Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method by Espinel-Ingroff, A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/153438
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Multicenter Study of Isavuconazole MIC Distributions and
Epidemiological Cutoff Values for the Cryptococcus neoformans-
Cryptococcus gattii Species Complex Using the CLSI M27-A3 Broth
Microdilution Method
A. Espinel-Ingroff,a A. Chowdhary,b G. M. Gonzalez,c J. Guinea,d F. Hagen,e J. F. Meis,e,f G. R. Thompson III,g J. Turnidgeh
VCU Medical Center, Richmond, Virginia, USAa; Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, Indiab; Universidad Autónoma de Nuevo León, Monterrey,
Nuevo León, Mexicoc; Hospital General Universitario Gregorio Marañón, School of Medicine-Universidad Complutense, Madrid, Spaind; Department of Medical
Microbiology & Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlandse; Department of Medical Microbiology, Radboud University Medical Center,
Nijmegen, The Netherlandsf; University of California Davis Medical Center, Davis, California, USAg; and University of Adelaide, Adelaide, Australiah
Epidemiological cutoff values (ECVs) of isavuconazole are not available for Cryptococcus spp. The isavuconazole ECVs based on
wild-type (WT) MIC distributions for 438 Cryptococcus neoformans nongenotyped isolates, 870 isolates of genotype VNI, and
406 Cryptococcus gattii isolates from six laboratories and different geographical areas were 0.06, 0.12, and 0.25g/ml, respec-
tively. These ECVsmay aid in detecting non-WT isolates with reduced susceptibilities to isavuconazole.
Infections caused by members of the Cryptococcus neoformans-Cryptococcus gattii species complex are considered the second
most common severe mycoses among immunocompromised and
nonimmunocompromised hosts in certain regions. Although in-
fections caused by C. neoformans var. grubii (serotype A) and, to a
lesser degree, by C. neoformans var. neoformans (serotype D) are
seen worldwide, those by C. gattii (serotypes B and C) are more
geographically restricted. Irrespective of the species, cryptococcal
disease is associated with high mortality rates (12.7%) (1–4). C.
neoformans var. grubii comprises genotypes VNI, VNII/VNB,
VNII (AFLP1, AFLP1A, AFLP1B), C. neoformans var. neoformans
comprises genotypes VNIV (AFLP2) and VNIII (AFLP3), and C.
gattii comprises genotypes VGI (AFLP4), VGII (AFLP6), VGIV
(AFLP10), VGIII (AFLP5), and VGIV (AFLP7) (1, 5–7). Ampho-
tericin B, its lipid formulations, and fluconazole are recom-
mended as the primary alternative induction treatments and/or as
salvage consolidation therapies for infections caused by C. neofor-
mans and C. gattii (3, 8). Isavuconazole (BAL4815, codeveloped
by Basilea Pharmaceutica International Ltd. [Basel, Switzerland]
and Astellas Pharma [Tokyo, Japan]) is a new water-soluble tria-
zole with favorable pharmacodynamic and pharmacokinetic pa-
rameters and is under clinical evaluation (phase III) for the treat-
ment of invasive aspergillosis and other mycoses. Isavuconazole’s
mode of action is the inhibition of ergosterol biosynthesis (en-
zymes 14--sterol demethylases A and B, which are encoded by
the cyp51 [ERG11] gene), similar to that of the other azoles. The in
vitro activity of isavuconazole is also similar to that of most li-
censed triazoles against Aspergillus spp., Candida spp., and Cryp-
tococcus spp.; it also has activity comparable to that of posacona-
zole and, to a certain extent, itraconazole against some Mucorales
species (9).
The Clinical and Laboratory Standards Institute (CLSI) has
established standard conditions for testing the susceptibilities of
Candida spp. and Aspergillus spp. to isavuconazole (10). In the
absence of clinical breakpoints (CBPs) (the ultimate means of
differentiating treatable and nontreatable isolates), epidemiolog-
ical cutoff values (ECVs) have been defined for the more prevalent
Candida spp. and the C. neoformans-C. gattii species complex ver-
sus those of the four licensed triazoles (11, 12). The ECV (also
known as the ECOFF or COWT) is the highest wild-type (WT)-
susceptible value; it is based on MIC distributions where there
are two distinct populations, (i) the WT population of isolates/
MICs with no detectable acquired or mutational resistance to
the drug being evaluated and (ii) the non-WT population or
isolates that harbor one or more resistance markers (13). The
ECV based on pooled data from multiple laboratories serves as
an early indication of emerging changes in the patterns of or-
ganism susceptibilities to the agent being evaluated or sepa-
rates WT from non-WT isolates. Although the in vitro activity
of isavuconazole against members of the C. neoformans-C. gattii
species complex has been evaluated by CLSI M27-A3 methodol-
ogy (14), ECVs based on data from multiple laboratories, as well as
different geographical areas, have not been established for this
complex. While data for the present study were submitted from a
total of seven laboratories, the distribution data from one of the
laboratories were abnormal (mode at the lower concentration
tested) and were not included in the analysis. In addition, MICs
were not submitted by each laboratory for each of the cryptococcal
groups evaluated. Therefore, the purpose of this study was to de-
fine isavuconazole ECVs for three groups within the C. neofor-
mans-C. gattii species complex for which MICs originated from
three or four of the six collaborating laboratories.
Each isolate originated from a unique clinical specimen. The
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CLSI broth microdilution isavuconazole MICs used for ECV def-
inition were obtained from the VCU Medical Center (Richmond,
VA), the Vallabhbhai Patel Chest Institute, University of Delhi
(Delhi, India), Universidad Autónoma de Nuevo León (Monter-
rey, Nuevo León, Mexico), the Department of Medical Microbi-
ology and Infectious Diseases, Canisius-Wilhelmina Hospital
(Nijmegen, The Netherlands), Department of Medical Microbiol-
ogy, Radboud University Medical Center (Nijmegen, The Neth-
erlands), and the University of California Davis Medical Center
(Davis, CA). Species, serotype, and molecular type identifications
were performed at each medical center using standard methodol-
ogies (15–19). We have aggregated CLSI MICs for 870 C. neofor-
mans (VNI molecular genotype), 438 C. neoformans nontyped,
and 406 C. gattii isolates (comprising the 5 molecular genotypes).
We also received a set of isavuconazole MICs for C. gattii environ-
mental isolates that were not incorporated in the analysis. The
MIC ranges for the control isolates (Candida parapsilosis ATCC
22019 and Candida krusei ATCC 6258) were within 3 to 4 dilu-
tions.
Our MICs were determined using CLSI testing parameters
(with standard RPMI 1640 broth [0.2% dextrose], final inoculum
concentrations that ranged from 0.4  103 to 5  103 CFU/ml,
and 72 h of incubation); the MICs were the lowest drug concen-
trations that produced50% growth inhibition compared to that
of the growth control (14). MIC distributions obtained in at least
three of the seven coded laboratories for each group were listed in
Excel spread sheets and aggregated for the ECV statistical calcula-
tion by a previously described method (13); the MICs that cap-
tured at least 95% and 97.5% of the modeled WT population
(instead of the observed values) were obtained. ECVs are not es-
timated when the distribution is grossly skewed, which precludes
statistical fitting, and a laboratory’s data are excluded when the
distribution from a single laboratory is truncated (mode at the
lower or upper end of the distribution). At least 100 MICs from
three independent laboratories are required for each group to es-
tablish an ECV. Because of that, we pooled the MICs for five mo-
lecular genotypes of C. gattii and used only the distributions for
the C. neoformans VNI genotype; data for the other genotypes
ranged from 13 to 172 MICs for VGI to VGIV genotypes and from
13 to 46 for VNII to VNIV genotypes, mostly inadequate sample
sizes for ECV calculation. In addition, 1 of the 4 C. neoformans
nontyped distributions received was truncated and was not
pooled for the analysis.
The ECV is the highest MIC of the WT population, while the
CBP is the MIC that predicts the clinical outcome of therapy (13,
20, 21). Therefore, the ECV detects the non-WT strains with re-
duced susceptibility (due to mutations) to the agent being evalu-
ated. Aggregated isavuconazole MIC distributions for C. neofor-
mans (genotype VNI), C. neoformans nontyped, and C. gattii
(pooled genotypes) isolates are shown in Table 1. Each of the three
pooled distributions had the same MIC range (0.008 to 0.5g/ml)
and mode (0.03 g/ml), and these values reflect an earlier report
of isavuconazole data for C. neoformans (22). Comparable results
have been observed with a larger number of isolates and the li-
censed triazoles for the three groups evaluated in the present
study: similar posaconazole and voriconazole ranges and modes 1
or 2 dilutions higher (0.06 to 0.12g/ml) (12). Our isavuconazole
ECVs comprising 95% of the modeled population were 0.06
g/ml (C. neoformansnontyped), 0.12g/ml (genotype VNI), and
0. 25 g/ml (C. gattii); the ECVs that comprised 97.5% of the
population were either the same or 1 dilution higher (Table 1).
Recently established itraconazole, posaconazole, and voricona-
zole ECVs for the same groups were 1 dilution higher (0.25 to 1
g/ml), with the highest ECVs for C. gattii (12). It is noteworthy
that the isavuconazole mode for the environmental C. gattii iso-
lates was 0.12 g/ml. Preliminary clinical data regarding isavu-
conazole treatment of cryptococcal infections was recently re-
ported (F. Queiroz-Telles, O. A. Cornely, J. Perfect, L. Kovanda, B.
Zeiher, and J. Vazquez, presented at the ICCAC Congress, Wash-
ington, DC, 5 to 9 September, 2014). Nine patients with either
central nervous system or disseminated cryptococcal disease were
treated with isavuconazole (200 mg three times daily for 2 days
followed by 200 mg every day [intravenous or oral]; VITAL phase
III, open-label, multicenter trial for the efficacy and safety of isa-
vuconazole). Of the eight patients evaluated on the 84th day, six
were treatment successes (including all C. gattii infections), and
two were treatment failures. CLSI isavuconazole MICs for the
seven available infecting C. neoformans and C. gattii isolates were
0.12 g/ml, which may be considered WT according to our
proposed ECVs (Table 1). These results underline the potential
values of ECV data in the clinical setting.
In conclusion, data originating in three laboratories for each of
the three groups enabled us to propose species-specific isavucona-
zole ECVs of 0.06 to 0.25 g/ml for the C. neoformans-C. gattii
species complex evaluated. The availability of standard CLSI pa-
rameters for testing isavuconazole against these species and the
ECVs calculated in the present study will aid in monitoring isavu-
conazole resistance in cryptococcal species and distinguishing
non-WT from WT isolates.
TABLE 1 Pooled MIC distributions and ECVs for the Cryptococcus neoformans-Cryptococcus gattii species complex and isavuconazole using the
CLSI M27-A3-RPMI microdilution methoda
Species
No. of
isolates
No. of isolates with an MICb (g/ml) of: ECV (g/ml)c
0.008 0.016 0.03 0.06 0.12 0.25 0.5
MIC range
(g/ml)
Mode
(g/ml)d 95% 97.5%
C. neoformans VNIe (AFLP1) 870 68 270 274 213 37 7 1 0.008–0.5 0.03 0.12 0.12
C. neoformans (nongenotyped) 438 10 135 170 96 19 6 2 0.008–0.5 0.03 0.06 0.12
C. gattiie 406 23 78 106 87 87 25 7 0.008–0.5 0.03 0.25 0.25
a MICs were pooled from three or four of the six collaborating laboratories that submitted qualifying data for each cryptococcal group.
b MICs as determined by the CLSI broth microdilution method using standard RPMI 1640 broth.
c ECVs comprising95% and97.5% of the statistically modeled MIC population.
d Most frequent MIC.
e C. gattii comprises the VGI through VGIV (also known as AFLP4 through AFLP7 and AFLP10) genotypes.
Isavuconazole ECVs for Cryptococcus spp.
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